Questcor's (QCOR -7.3%) early drubbing was apparently due to a mistaken headline stating that a...
Questcor's (QCOR -7.3%) early drubbing was apparently due to a mistaken headline stating that a synthetic version of Acthar had been approved by the FDA, rather than the Orphan Drug Designation it had actually been given, according to a Seeking Alpha contributor. The errant headline has since been pulled and refiled to reflect the correction, but the hangover in the shares continues in mid-day trading nontheless.
From other sites
at Zacks.com (Tue, 1:30PM)
at Zacks.com (Mon, 3:59PM)
at Zacks.com (Mon, 8:57AM)
at 4-traders.com (Mon, 7:01AM)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs